HOME >> BIOLOGY >> NEWS
Migration study finds that sweeping management changes are needed to protect Atlantic bluefin tuna

A team of marine scientists has mapped the undersea journeys of Atlantic bluefin tuna and concluded that tighter restrictions should be placed on commercial fishing to protect the feeding and breeding grounds of this top migratory predator--one of the most commercially valuable fish in the sea.

Researchers from Stanford University and the Monterey Bay Aquarium say that their new study, published in the April 28 edition of the journal Nature, offers substantial evidence that significant changes need to be made in how Atlantic bluefin tuna fisheries are managed internationally and in the United States.

"In my lifetime we've brought this majestic species to the doorstep of ecological extinction in the western Atlantic Ocean," says Barbara A. Block, the Charles and Elizabeth Prothro Professor in Marine Sciences at Stanford's Hopkins Marine Station and lead author of the Nature study. "Electronic tagging provides the best scientific information we've ever had to properly manage these tuna and we must, as an international community, start to act responsibly to ensure the future of this species."

An expert on large migratory fish, Block is a founder and the co-director of the Tuna Research and Conservation Center (TRCC), a joint collaboration between Stanford and the Monterey Bay Aquarium. For the past 10 years, she and her colleagues have braved the rough waters of the Atlantic Ocean to carry out an unprecedented study of bluefin tuna migrations. Working with sport and commercial fishers in the Carolinas and New England, as well as commercial fleets in the Gulf of Mexico, TRCC researchers have placed electronic tags on hundreds of wild bluefin tuna ranging in size from 150 to 900 pounds. The tags track individual fish as they travel thousands of miles across the sea, to depths below 3,000 feet, in search of food and mates. Each tag records the tuna's migration pattern, diving behavior, body temperature and the temperature of the surrounding water.<
'"/>

Contact: Mark Shwartz
mshwartz@stanford.edu
650-723-9296
Stanford University
27-Apr-2005


Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. Migration alert -- How tumor cells home in on the lymphatic system
2. New study warns limited carbon market puts 20 percent of tropical forest at risk
3. Clones on task serve greater good, evolutionary study shows
4. Pollution causes 40 percent of deaths worldwide, study finds
5. A study by the MUHC and McGill University opens a new door to understanding cancer
6. New study suggests Concord grape juice may provide protection against breast cancer
7. Preclinical study links gene to brain aneurysm formation
8. In limiting life span, study finds booming bacteria innocent
9. Multicenter study nets new lung tumor-suppressor gene
10. MIT study: Maturity brings richer memories
11. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study

Post Your Comments:
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: